Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu

Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu

Chronic hyperglycemia induces pathophysiologic pathways with negative effects on the metabolism of most substrates as well as lipids and lipoproteins, and thereby induces dyslipidemia. Thus, the diabetic milieu is commonly accompanied by different levels of atherogenic dyslipidemia, which is <i&g...

Full description

Bibliographic Details
Main Authors:	Habib Yaribeygi, Mina Maleki, Željko Reiner, Tannaz Jamialahmadi, Amirhossein Sahebkar
Format:	Article
Language:	English
Published:	MDPI AG 2022-11-01
Series:	Journal of Clinical Medicine
Subjects:	diabetes mellitus sodium-glucose cotransporter-2 inhibitors lipids cholesterol lipogenesis lipolysis
Online Access:	https://www.mdpi.com/2077-0383/11/21/6544

Similar Items

Modulating effects of crocin on lipids and lipoproteins: Mechanisms and potential benefits
by: Habib Yaribeygi, et al.
Published: (2024-04-01)

Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions
by: Habib Yaribeygi, et al.
Published: (2023-01-01)

Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
by: Habib Yaribeygi, et al.
Published: (2023-04-01)

Effects of SGLT2 inhibition on lipid transport in adipose tissue in type 2 diabetes
by: Katrine M Lauritsen, et al.
Published: (2022-04-01)

Gender and age effects on the expression of genes related to lipid metabolism in broiler's liver
by: Angélica de Souza Khatlab, et al.
Published: (2018-03-01)

Differences in lipogenesis and lipolysis in obese and non-obese adult human adipocytes
by: MARIANA CIFUENTES, et al.
Published: (2008-01-01)

SGLT2 Inhibitors as Potential Anticancer Agents
by: Debasish Basak, et al.
Published: (2023-06-01)

Renin-angiotensin system blockers regulate the metabolism of isolated fat cells in vitro
by: R de O. Caminhotto, et al.
Published: (2016-07-01)

Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms
by: Keming Huang, et al.
Published: (2023-04-01)

Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta‐Analysis of Randomized‐Controlled Trials
by: Yao Hao Teo, et al.
Published: (2021-03-01)

Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy
by: David Bobrowski, et al.
Published: (2021-11-01)

Sodium–glucose cotransporters: Functional properties and pharmaceutical potential
by: Ryuhei Sano, et al.
Published: (2020-07-01)

Effect of ractopamine on lipid metabolism in vivo - a systematic review
by: Matheus Soares da Silva Ferreira, et al.
Published: (2013-02-01)

Anti-inflammatory benefits of semaglutide: State of the art
by: Habib Yaribeygi, et al.
Published: (2024-06-01)

SGLT2 inhibitors in peritoneal dialysis: a promising frontier toward improved patient outcomes
by: Natalia Stepanova
Published: (2024-01-01)

Unveiling the anticancer effects of SGLT-2i: mechanisms and therapeutic potential
by: Min Sun, et al.
Published: (2024-03-01)

Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure
by: Akshyaya Pradhan, et al.
Published: (2019-01-01)

SGLT2 inhibitor versus carbohydrate-restricted isocaloric diet: reprogramming substrate oxidation in type 2 diabetes
by: Hiroyuki Igarashi, et al.
Published: (2023-02-01)

Effects of SGLT2 inhibitor on tumor‐releasing chemokines/cytokines in Hep3B and Huh7 cells
by: Dan Nakano, et al.
Published: (2022-04-01)

Regulatory Effects of Metformin, an Antidiabetic Biguanide Drug, on the Metabolism of Primary Rat Adipocytes
by: Tomasz Szkudelski, et al.
Published: (2022-08-01)

Succinate Enhances Lipolysis and Decreases Adipocytes Size in Both Subcutaneous and Visceral Adipose Tissue from High-Fat-Diet-Fed Obese Mice
by: Tengteng Ji, et al.
Published: (2023-11-01)

The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice
by: Ellen Vercalsteren, et al.
Published: (2024-02-01)

Left Ventricular SGLT1 Protein Expression Correlates with the Extent of Myocardial Nitro-Oxidative Stress in Rats with Pressure and Volume Overload-Induced Heart Failure
by: Alex Ali Sayour, et al.
Published: (2021-07-01)

Adipose KLF15 Controls Lipid Handling to Adapt to Nutrient Availability
by: Keiichiro Matoba, et al.
Published: (2017-12-01)

SGLT1 Knockdown Attenuates Cardiac Fibroblast Activation in Diabetic Cardiac Fibrosis
by: Hui Lin, et al.
Published: (2021-06-01)

Alcohol, White Adipose Tissue, and Brown Adipose Tissue: Mechanistic Links to Lipogenesis and Lipolysis
by: Qing Li, et al.
Published: (2023-06-01)

Dapagliflozin protects against nonalcoholic steatohepatitis in db/db mice
by: Panshuang Qiao, et al.
Published: (2022-08-01)

SGLT2-Inhibitors and Euglycemia Diabetic Ketoacidosis: A Missed Diagnosis
by: Muhammad Nadeem Ahmed Khan, et al.
Published: (2023-12-01)

Association of common variant rs9934336 of SLC5A2 (SGLT2) gene with SARS-CoV-2 infection and mortality
by: Anamika Das, et al.
Published: (2024-01-01)

Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches
by: Yu Zhang, et al.
Published: (2023-06-01)

Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors
by: Weronika Frąk, et al.
Published: (2023-07-01)

Repurposing SGLT-2 Inhibitors to Target Aging: Available Evidence and Molecular Mechanisms
by: Rosalba La Grotta, et al.
Published: (2022-10-01)

Effects of an SGLT Inhibitor on the Production, Toxicity, and Elimination of Gut-Derived Uremic Toxins: A Call for Additional Evidence
by: Pieter Evenepoel, et al.
Published: (2022-03-01)

Head-to-head comparison of two SGLT-2 inhibitors on AKI outcomes in a rat ischemia-reperfusion model
by: Chang Chu, et al.
Published: (2022-09-01)

Lack of durable natriuresis and objective decongestion following SGLT2 inhibition in randomized controlled trials of patients with heart failure
by: Milton Packer
Published: (2023-08-01)

SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study
by: Jiang Li, et al.
Published: (2023-10-01)

SGLT1: A Potential Drug Target for Cardiovascular Disease
by: Zhao M, et al.
Published: (2023-07-01)

Adropin Slightly Modulates Lipolysis, Lipogenesis and Expression of Adipokines but Not Glucose Uptake in Rodent Adipocytes
by: Mariami Jasaszwili, et al.
Published: (2021-06-01)

Direct cardiac effects of SGLT2 inhibitors
by: Sha Chen, et al.
Published: (2022-03-01)

Redox Regulation of Lipid Mobilization in Adipose Tissues
by: Ursula Abou-Rjeileh, et al.
Published: (2021-07-01)